Skip to main content

Table 1 Experimental design

From: IVIg protects the 3xTg-AD mouse model of Alzheimer’s disease from memory deficit and Aβ pathology

Age at beginning Treatment duration Group/treatment Age at sacrifice Behavioral tests Postmortem analyses
Experiment I
9.0 ± 0.1 months of age 3-month treatment 27 i.p. injections (two/week) 12.0 ± 0.1 months of age Novel object recognition (NOR) task Brain: ELISA quantification, Western blots, immunohistochemistry and immunofluorescence
NonTg: ctrl (n = 8, 50% F) Dark-light box emergence test Blood, whole blood and plasma: saphenous vein blood (after 25 injections), flow cytometry and ELISA
3xTg-AD: ctrl (n = 13, 54% F)/1.5 g/kg IVIg (n = 12, 50% F) Bone marrow, cells: flow cytometry
Ctrl/vehicle: endotoxin free glycine 0.2 M pH 4.25 Splenocytes: flow cytometry and ELISPOT
Experiment II  
12.9 ± 0.2 and 14.8 ± 0.2 months of age 3-month treatment 27 i.p. injections (two/week) (12.9 ± 0.2 months of age) 15.9 ± 0.2 months of age NOR task Brain: ELISA quantification, Western blots
NonTg: ctrl (n = 8, 50% F)/1.5 g/kg IVIg (n = 8, 50% F) Barnes maze (3xTg-AD mice, 3-month treatment only) Blood, whole blood and plasma: intracardiac blood (at sacrifice), flow cytometry and ELISA
3xTg-AD: ctrl (n = 14, 50% F)/1.5 g/kg IVIg (n = 13, 46% F) Open field
1-month treatment Nine i.p. injections (two/week) (14.8 ± 0.2 months of age)
NonTg: ctrl (n = 8, 50% F)
  3xTg-AD: ctrl (n = 14, 50% F)/1.5 g/kg IVIg (n = 13, 46% F)    
  1. IVIg, Gamunex™ (Grifols Canada Ltd., Mississauga, ON, Canada). 3xTg-AD, triple-transgenic mouse model of Alzheimer’s disease; ctrl, control; ELISA, enzyme-linked immunosorbent assay; ELISPOT, enzyme-linked immunosorbent spot; F, female; i.p., intraperitoneal; IVIg, intravenous immunoglobulin; NonTg, non-transgenic; NOR, novel object recognition.